News | July 24, 2025
Pfizer completes licensing agreement with 3SBio to expand oncology portfolio
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
_256_384.jpg)
iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus
Upgrades 2025 full-year CDMO sales and margin outlook
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
Subscribe To Our Newsletter & Stay Updated
